Brii Biosciences Limited (HK:2137)
:2137
Want to see HK:2137 full AI Analyst Report?
Total Valuation
Brii Biosciences Limited has a market cap or net worth of HK$967.22M. The enterprise value is HK$239.21M.
Market CapHK$967.22M
Enterprise ValueHK$239.21M
Share Statistics
Brii Biosciences Limited has 734,530,500 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding734,530,500
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Brii Biosciences Limited’s return on equity (ROE) is -0.09 and return on invested capital (ROIC) is -12.68%.
Return on Equity (ROE)-0.09
Return on Assets (ROA)-0.09
Return on Invested Capital (ROIC)-12.68%
Return on Capital Employed (ROCE)-0.13
Revenue Per Employee184.93K
Profits Per Employee-2.21M
Employee Count98
Asset Turnover<0.01
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Brii Biosciences Limited is ―. Brii Biosciences Limited’s PEG ratio is 0.07.
PE Ratio―
PS Ratio50.44
PB Ratio0.38
Price to Fair Value0.38
Price to FCF-3.17
Price to Operating Cash Flow-8.05
PEG Ratio0.07
Income Statement
In the last 12 months, Brii Biosciences Limited had revenue of 18.12M and earned -216.86M in profits. Earnings per share was -0.30.
Revenue18.12M
Gross Profit0.00
Operating Income-295.88M
Pretax Income-216.42M
Net Income-216.86M
EBITDA-290.29M
Earnings Per Share (EPS)-0.30
Cash Flow
In the last 12 months, operating cash flow was -103.83M and capital expenditures -1.86M, giving a free cash flow of -105.69M billion.
Operating Cash Flow-103.83M
Free Cash Flow-105.69M
Free Cash Flow per Share-0.14
Dividends & Yields
Brii Biosciences Limited pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.45
52-Week Price Change-29.47%
50-Day Moving Average1.46
200-Day Moving Average1.73
Relative Strength Index (RSI)57.26
Average Volume (3m)6.36M
Important Dates
Brii Biosciences Limited upcoming earnings date is Aug 20, 2026, TBA (Confirmed).
Last Earnings DateMar 19, 2026
Next Earnings DateAug 20, 2026
Ex-Dividend Date―
Financial Position
Brii Biosciences Limited as a current ratio of 60.73, with Debt / Equity ratio of 0.38%
Current Ratio60.73
Quick Ratio60.73
Debt to Market Cap<0.01
Net Debt to EBITDA2.07
Interest Coverage Ratio-154.89
Taxes
In the past 12 months, Brii Biosciences Limited has paid 1.85M in taxes.
Income Tax1.85M
Effective Tax Rate>-0.01
Enterprise Valuation
Brii Biosciences Limited EV to EBITDA ratio is -1.08, with an EV/FCF ratio of -1.09.
EV to Sales17.35
EV to EBITDA-1.08
EV to Free Cash Flow-1.09
EV to Operating Cash Flow-1.10
Balance Sheet
Brii Biosciences Limited has HK$1.94B in cash and marketable securities with HK$8.93M in debt, giving a net cash position of HK$1.93B billion.
Cash & Marketable SecuritiesHK$1.94B
Total DebtHK$8.93M
Net CashHK$1.93B
Net Cash Per ShareHK$2.63
Tangible Book Value Per ShareHK$2.81
Margins
Gross margin is 5.15%, with operating margin of -1632.59%, and net profit margin of -1196.58%.
Gross Margin5.15%
Operating Margin-1632.59%
Pretax Margin-1194.13%
Net Profit Margin-1196.58%
EBITDA Margin-1601.74%
EBIT Margin-1632.59%
Analyst Forecast
The average price target for Brii Biosciences Limited is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast―
EPS Growth Forecast55.86%